Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 3/20 | 0.41 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.40 |
| ▸ | GALR2 | O43603 | 1/20 | 0.40 |
| ▸ | GALR1 | P47211 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3108841 | 0.97 | GALR2 (0.44) | KDM1ATLR9GALR2GALR1LMNA | |
| SCHEMBL3108033 | 0.92 | AOC3 (0.38) | KDM1ATLR9GALR2GALR1LMNA | |
| SCHEMBL4864644 | 0.91 | TLR9 (0.40) | KDM1ATLR9GALR2GALR1LMNA | |
| SCHEMBL3106664 | 0.88 | ALDH1A1 (0.45) | KDM1AGALR2GALR1GPR119ALDH1A1 | |
| SCHEMBL3101367 | 0.87 | ALDH1A1 (0.41) | KDM1AMAPTALDH1A1 | |
| SCHEMBL3103511 | 0.87 | AXL (0.40) | ALDH1A1TLR7 | |
| SCHEMBL1944319 | 0.86 | GPR119 (0.41) | KDM1AGPR119ALDH1A1 | |
| SCHEMBL3114724 | 0.86 | BACE1 (0.39) | KDM1AGPR119ALDH1A1TLR7 | |
| SCHEMBL1945933 | 0.86 | KDM1A (0.39) | KDM1AGPR119ALDH1A1 | |
| SCHEMBL1944155 | 0.86 | SLC2A1 (0.42) | KDM1AGPR119ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2010-10-07 | — | — | US | disclosed |
| US-7723330-B2 | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC. (US) | 2010-05-25 | — | — | US | disclosed |
| CN-101437820-A | Heterobicyclic pyrazole compounds and methods of use | ARRAY BIOPHARMA INC (US) | 2009-05-20 | — | — | CN | disclosed |
| EP-2001880-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | Array Biopharma, Inc. (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | GENENTECH, INC. | 2007-10-11 | — | — | US | disclosed |
| WO-2007103308-A2 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ARRAY BIOPHARMA INC. (US) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256356-A1 | HETEROBICYCLIC PYRAZOLE COMPOUNDS AND METHODS OF USE | ROR1, CYP11B1, CYP11B2 | KDM1A 4831/4885TLR9 2975/4885GALR2 964/4885 |
| US-20070238726-A1 | Heterobicyclic pyrazole compounds and methods of use | ROR1, CYP11B1, CYP11B2 | KDM1A 4831/4885TLR9 2975/4885GALR2 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.